 |
|
Level of Agreement With the British Guidelines for the Use of Biological Therapies for Psoriasis
Tamar Nijsten, MD, PhD
Arch Dermatol. 2007;143(12):1567-1569.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Commentary on: British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005
Smith CH, Anstey AV, Barker JN, et al
Br J Dermatol. 2005;153(3):486-497
Question: When, who, and how to prescribe biological therapies for psoriasis in the United Kingdom?
Setting: British Association of Dermatologists (BAD) guideline working group.
Design: The BAD group developed guidelines for the use of biological interventions in psoriasis 2005. They used BAD-recommended methodology and the AGREE (Appraisal of Guidelines for Research and Evaluation) instrument. A literature review was performed by searching EMBASE and Medline (1990–early 2005) for clinical psoriasis trials involving efalizumab, etanercept, and infliximab using an agreed-on protocol. Included manuscripts were scored using the NICE (National Institute for Clinical Excellence) criteria for level of evidence and strength of recommendation. The pharmacology, clinical effectiveness, dosing regimens, and toxicity of the biological agents are reviewed. Three key questions (Which patients . . . [Full Text of this Article] Comment
AUTHOR INFORMATION
Erasmus Medical Center, Rotterdam, the Netherlands
RELATED ARTICLE
British Guidelines on the Use of Biological Therapies for Psoriasis: A Note of Clarification on the Role of Etanercept
Catherine H. Smith and Anthony D. Ormerod
Arch Dermatol. 2007;143(12):1595-1596.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
British Guidelines on the Use of Biological Therapies for Psoriasis: A Note of Clarification on the Role of Etanercept
Smith and Ormerod
Arch Dermatol 2007;143:1595-1596.
FULL TEXT
|
